Related references
Note: Only part of the references are listed.Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study
K. Krause et al.
ALLERGY (2012)
Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome
Karoline Krause et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome
Heleen D. de Koning et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature
J. T. Gran et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2011)
Canakinumab (ACZ885, a fully human IgG1 anti-IL-1 beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
Jasmin B. Kuemmerle-Deschner et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review
Emilio Besada et al.
CLINICAL RHEUMATOLOGY (2010)
Schnitzler syndrome: response to anakinra in two cases and a review of the literature
Christian Schuster et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2009)
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Helen J. Lachmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Helen J. Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IL-1 blockade in Schnitzler syndrome: Ex vivo findings correlate with clinical remission
John G. Ryan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Beneficial response to anakinra and thalidomide in Schnitzler's syndrome
HD de Koning et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
The RAND-36 measure of health-related quality of life
RD Hays et al.
ANNALS OF MEDICINE (2001)
The Schnitzler syndrome - Four new cases and review of the literature
D Lipsker et al.
MEDICINE (2001)